Clinical Trial Update: A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing camrelizumab plus chemotherapy versus placebo plus chemotherapy as neoadjuvant therapy in triple negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: COMPLETED